Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030239097> ?p ?o ?g. }
- W3030239097 endingPage "10507" @default.
- W3030239097 startingPage "10507" @default.
- W3030239097 abstract "10507 Background: In pediatric patients with solid tumors, regorafenib demonstrated acceptable tolerability and preliminary anti-tumor activity. This phase 1 study evaluated regorafenib in combination with vincristine/irinotecan in pediatric patients with rhabdomyosarcoma (RMS) and other solid tumors. Methods: Patients with relapsed/refractory tumors received intravenous vincristine (1.5 mg/m 2 , Days 1 and 8) and irinotecan (50 mg/m 2 /day, Days 1–5) plus once-daily oral regorafenib (patients 6– < 24 months: 60 mg/m 2 escalating to 65 mg/m 2 ; patients 2– < 18 years: 72 mg/m 2 escalating to 82 mg/m 2 ) on either Days 1–14 (concomitant dosing) or Days 8–21 (sequential dosing) during each 21-day cycle. As per protocol, at least 50% of patients were required to have RMS. Results: At the time of the cut-off, of 21 treated patients (RMS, n = 12; Ewing sarcoma, n = 5; neuroblastoma, n = 3; Wilms tumor, n = 1), two had concomitant (72 mg/m 2 ) and 19 had sequential (72 mg/m 2 , n = 6; 82 mg/m 2 , n = 13) dosing. Median age was 10 years (1.5–17.0). Patients received a median of 3 cycles (1–17); dose reductions of irinotecan occurred in 62% of patients. Grade 3 dose-limiting toxicities were reported in both patients receiving concomitant dosing (peripheral neuropathy and liver injury; pain, vomiting, febrile aplasia) and one patient each in the sequential groups (rash and elevated AST; thrombocytopenia). Concomitant dosing was discontinued. The maximum tolerated dose and recommended phase 2 dose (RP2D) of regorafenib in the sequential combination was 82 mg/m 2 . The most common grade ≥3 treatment-emergent adverse events were neutropenia (71%), thrombocytopenia (33%), leukopenia (29%), anemia (24%), and ALT increased (24%). The response rate was 38%, including 1 complete (RMS) and 7 partial responders (5 RMS, 2 Ewing sarcoma); 3 of whom had prior irinotecan. Six (4 with alveolar subtype) of 12 patients with RMS had a response. Nine patients (43%) had stable disease (maximum duration 17 cycles). After the cut-off, partial response was reported for two additional patients (1 RMS, 1 Ewing sarcoma). Conclusions: Regorafenib can be combined at its single agent RP2D of 82 mg/m 2 with standard-dose vincristine/irinotecan (with appropriate dose modifications) in pediatric patients with refractory/relapsed solid tumors in a sequential dosing schedule. Clinical activity was observed in patients with sarcoma. Clinical trial information: NCT02085148." @default.
- W3030239097 created "2020-06-05" @default.
- W3030239097 creator A5004458586 @default.
- W3030239097 creator A5006570922 @default.
- W3030239097 creator A5017280045 @default.
- W3030239097 creator A5022270805 @default.
- W3030239097 creator A5030873065 @default.
- W3030239097 creator A5036070143 @default.
- W3030239097 creator A5041372516 @default.
- W3030239097 creator A5041891988 @default.
- W3030239097 creator A5043433926 @default.
- W3030239097 creator A5051922909 @default.
- W3030239097 creator A5052857128 @default.
- W3030239097 creator A5083350260 @default.
- W3030239097 creator A5085820190 @default.
- W3030239097 date "2020-05-20" @default.
- W3030239097 modified "2023-10-17" @default.
- W3030239097 title "Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors." @default.
- W3030239097 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.10507" @default.
- W3030239097 hasPublicationYear "2020" @default.
- W3030239097 type Work @default.
- W3030239097 sameAs 3030239097 @default.
- W3030239097 citedByCount "6" @default.
- W3030239097 countsByYear W30302390972021 @default.
- W3030239097 countsByYear W30302390972022 @default.
- W3030239097 countsByYear W30302390972023 @default.
- W3030239097 crossrefType "journal-article" @default.
- W3030239097 hasAuthorship W3030239097A5004458586 @default.
- W3030239097 hasAuthorship W3030239097A5006570922 @default.
- W3030239097 hasAuthorship W3030239097A5017280045 @default.
- W3030239097 hasAuthorship W3030239097A5022270805 @default.
- W3030239097 hasAuthorship W3030239097A5030873065 @default.
- W3030239097 hasAuthorship W3030239097A5036070143 @default.
- W3030239097 hasAuthorship W3030239097A5041372516 @default.
- W3030239097 hasAuthorship W3030239097A5041891988 @default.
- W3030239097 hasAuthorship W3030239097A5043433926 @default.
- W3030239097 hasAuthorship W3030239097A5051922909 @default.
- W3030239097 hasAuthorship W3030239097A5052857128 @default.
- W3030239097 hasAuthorship W3030239097A5083350260 @default.
- W3030239097 hasAuthorship W3030239097A5085820190 @default.
- W3030239097 hasConcept C121332964 @default.
- W3030239097 hasConcept C121608353 @default.
- W3030239097 hasConcept C126322002 @default.
- W3030239097 hasConcept C141071460 @default.
- W3030239097 hasConcept C142424586 @default.
- W3030239097 hasConcept C142724271 @default.
- W3030239097 hasConcept C197934379 @default.
- W3030239097 hasConcept C2776248978 @default.
- W3030239097 hasConcept C2776694085 @default.
- W3030239097 hasConcept C2776755627 @default.
- W3030239097 hasConcept C2777288759 @default.
- W3030239097 hasConcept C2778256501 @default.
- W3030239097 hasConcept C2778375690 @default.
- W3030239097 hasConcept C2778570526 @default.
- W3030239097 hasConcept C2779384505 @default.
- W3030239097 hasConcept C2779429289 @default.
- W3030239097 hasConcept C2780259306 @default.
- W3030239097 hasConcept C2780844630 @default.
- W3030239097 hasConcept C2780852908 @default.
- W3030239097 hasConcept C526805850 @default.
- W3030239097 hasConcept C71924100 @default.
- W3030239097 hasConcept C87355193 @default.
- W3030239097 hasConcept C90924648 @default.
- W3030239097 hasConceptScore W3030239097C121332964 @default.
- W3030239097 hasConceptScore W3030239097C121608353 @default.
- W3030239097 hasConceptScore W3030239097C126322002 @default.
- W3030239097 hasConceptScore W3030239097C141071460 @default.
- W3030239097 hasConceptScore W3030239097C142424586 @default.
- W3030239097 hasConceptScore W3030239097C142724271 @default.
- W3030239097 hasConceptScore W3030239097C197934379 @default.
- W3030239097 hasConceptScore W3030239097C2776248978 @default.
- W3030239097 hasConceptScore W3030239097C2776694085 @default.
- W3030239097 hasConceptScore W3030239097C2776755627 @default.
- W3030239097 hasConceptScore W3030239097C2777288759 @default.
- W3030239097 hasConceptScore W3030239097C2778256501 @default.
- W3030239097 hasConceptScore W3030239097C2778375690 @default.
- W3030239097 hasConceptScore W3030239097C2778570526 @default.
- W3030239097 hasConceptScore W3030239097C2779384505 @default.
- W3030239097 hasConceptScore W3030239097C2779429289 @default.
- W3030239097 hasConceptScore W3030239097C2780259306 @default.
- W3030239097 hasConceptScore W3030239097C2780844630 @default.
- W3030239097 hasConceptScore W3030239097C2780852908 @default.
- W3030239097 hasConceptScore W3030239097C526805850 @default.
- W3030239097 hasConceptScore W3030239097C71924100 @default.
- W3030239097 hasConceptScore W3030239097C87355193 @default.
- W3030239097 hasConceptScore W3030239097C90924648 @default.
- W3030239097 hasIssue "15_suppl" @default.
- W3030239097 hasLocation W30302390971 @default.
- W3030239097 hasOpenAccess W3030239097 @default.
- W3030239097 hasPrimaryLocation W30302390971 @default.
- W3030239097 hasRelatedWork W150272611 @default.
- W3030239097 hasRelatedWork W2112772060 @default.
- W3030239097 hasRelatedWork W2149228256 @default.
- W3030239097 hasRelatedWork W2332945896 @default.
- W3030239097 hasRelatedWork W2795629919 @default.
- W3030239097 hasRelatedWork W2997140747 @default.
- W3030239097 hasRelatedWork W3006860517 @default.
- W3030239097 hasRelatedWork W3030239097 @default.